Wells Fargo & Company Cuts Bio-Techne (NASDAQ:TECH) Price Target to $62.00

Bio-Techne (NASDAQ:TECH) had its price objective dropped by equities researchers at Wells Fargo & Company from $76.00 to $62.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price would indicate a potential upside of 26.85% from the company’s current price.

TECH has been the subject of several other reports. Citigroup reiterated a “buy” rating and issued a $80.00 target price (up from $70.00) on shares of Bio-Techne in a research report on Wednesday, February 4th. Weiss Ratings downgraded Bio-Techne from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Stifel Nicolaus set a $50.00 target price on Bio-Techne in a research report on Thursday. UBS Group restated a “buy” rating and set a $79.00 price objective (up from $70.00) on shares of Bio-Techne in a research report on Thursday, February 5th. Finally, Evercore set a $50.00 price objective on Bio-Techne in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Bio-Techne has an average rating of “Moderate Buy” and a consensus target price of $67.54.

Bio-Techne Price Performance

Shares of TECH traded up $1.48 during trading hours on Thursday, hitting $48.88. 1,484,852 shares of the company were exchanged, compared to its average volume of 2,425,626. The company has a quick ratio of 3.08, a current ratio of 4.54 and a debt-to-equity ratio of 0.13. Bio-Techne has a fifty-two week low of $45.12 and a fifty-two week high of $72.16. The company has a market cap of $7.65 billion, a price-to-earnings ratio of 96.09, a P/E/G ratio of 3.73 and a beta of 1.41. The firm’s fifty day moving average is $54.55 and its 200 day moving average is $59.61.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.02). The business had revenue of $311.42 million for the quarter, compared to the consensus estimate of $316.11 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.Bio-Techne’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.56 earnings per share. On average, equities analysts anticipate that Bio-Techne will post 1.73 earnings per share for the current fiscal year.

Institutional Trading of Bio-Techne

Several institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its holdings in shares of Bio-Techne by 349.8% in the third quarter. Wellington Management Group LLP now owns 5,115,133 shares of the biotechnology company’s stock worth $284,555,000 after purchasing an additional 3,978,026 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Bio-Techne by 164.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,012,818 shares of the biotechnology company’s stock worth $235,994,000 after purchasing an additional 2,495,328 shares during the period. Norges Bank acquired a new stake in Bio-Techne during the 4th quarter worth about $99,494,000. Durable Capital Partners LP purchased a new stake in shares of Bio-Techne during the 3rd quarter worth about $77,658,000. Finally, Morgan Stanley boosted its stake in shares of Bio-Techne by 15.3% during the 4th quarter. Morgan Stanley now owns 8,345,414 shares of the biotechnology company’s stock worth $490,794,000 after acquiring an additional 1,107,536 shares in the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Techne News Roundup

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Management is targeting roughly 100 basis points of margin expansion in Q4 and expects organic growth to be approximately flat, which investors may view as credible margin-driven earnings leverage. Bio-Techne expects Q4 organic growth approximately flat while targeting ~100 bps margin expansion
• Positive Sentiment: Board declared a quarterly dividend of $0.08/share (payable May 29; record May 18), providing incremental income appeal and signalling cash-flow confidence. Bio-Techne Declares Dividend
• Positive Sentiment: Management highlighted strong growth in key product vectors (mid-single-digit Proteomic Analysis instruments, mid-teens Spatial Biology, ~50% GMP proteins ex fast‑track customers), which could support future revenue recovery. Bio-Techne Releases Third Quarter Fiscal 2026 Results
• Neutral Sentiment: Full earnings call transcript and corporate release are available for investors to parse for details on shipment timing, GMP orders and end‑market dynamics. Q3 2026 Earnings Call Transcript
• Negative Sentiment: Q3 revenue of $311.4M missed consensus (~$316M) and was down ~2% year-over-year; adjusted EPS $0.53 missed estimates and fell from $0.56 a year ago — the main driver of the initial selloff. TECH Stock Falls on Q3 Earnings & Revenue Miss, Operating Margin Up
• Negative Sentiment: Company cited weaker demand from U.S. academic customers due to funding cuts and timing of large commercial supply shipments (including prior-year GMP fast‑track orders) as headwinds to growth. Bio-Techne misses revenue estimates as US academic funding cuts dent demand
• Negative Sentiment: Market reaction included a sharp intraday slide after the results; some outlets and scanners flagged the revenue/EPS miss as the key reason for selling pressure. Bio-Techne slides after fiscal Q3 results

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.